Lentivirus vector mobilization and spread by human immunodeficiency virus

Area of Science:

• Gene Therapy
• Retroviral Vectors
• Viral Safety

Background:

• Lentivirus vectors are advanced gene transfer systems with broad applications.
• Clinical use necessitates rigorous safety evaluations, particularly concerning replication-competent retroviruses and vector mobilization.
• Vector mobilization by wild-type helper virus (rescue) is a key safety concern for lentiviral vector preparations.

Purpose of the Study:

• To establish an in vitro system for studying lentivirus-based vector rescue by wild-type human immunodeficiency virus (HIV).
• To assess the potential for lentiviral vector spread mediated by HIV in different cell types.
• To investigate methods for preventing lentiviral vector mobilization.

Main Methods:

• Development of an in vitro system to model lentiviral vector rescue by wild-type HIV.
• Transduction of T cell lines and primary human lymphocytes with lentiviral vectors.
• Co-cultivation with wild-type HIV to assess vector mobilization and spread.
• Evaluation of antiretroviral drugs, such as AZT, for their ability to inhibit vector mobilization.

Main Results:

• Lentivirus-based vectors were readily rescued from T cell lines and, to a lesser extent, from primary human lymphocytes by wild-type HIV.
• Mobilized vector particles spread to previously untransduced cells, indicating efficient vector dissemination.
• Antiretroviral drugs, including AZT, effectively prevented lentiviral vector mobilization.
• The lentiviral vectors used did not significantly impact HIV replication or spread in transduced cells.

Conclusions:

• Lentiviral vector mobilization by HIV is a demonstrable in vitro phenomenon with implications for gene therapy safety.
• Antiretroviral drug treatment offers a potential strategy to mitigate the risk of lentiviral vector spread.
• While vector spread is generally a safety concern, it may offer therapeutic benefits in the context of gene therapy for HIV infection.